Arcus Biosciences Inc. (RCUS)
RCUS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$22.51
-7.52% on the day
Market cap
$2.9B
Mid cap
Revenue · 2025
$247.0M
-4.3% on 2024
Net income · 2025
-$353.0M
-142.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | RCUS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001724521 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $247.0M |
| Net income | -$353.0M |
| Operating income | -$386.0M |
| Net margin | -142.9% |
| Operating margin | -156.3% |
| Revenue growth | -4.3% |
| Cash | $222.0M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 602 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.7% |
| 1 month | -7.0% |
| 3 months | -15.1% |
| Year to date | -5.1% |
| 1 year | +35.9% |
| From 52-week high | -28.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DYN | Dyne Therapeutics Inc. | $15.30 | -4.13% | $2.9B |
| ELVN | Enliven Therapeutics Inc. | $39.49 | -3.31% | $2.9B |
| PGEN | Precigen Inc. | $7.48 | -2.35% | $2.7B |
| ZLAB | Zai Lab Limited | $23.10 | -6.06% | $2.6B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.62 | -4.07% | $3.2B |
| VCRE | Vicore Pharma Holding AB | $8.95 | -3.03% | $2.5B |
| PBLS | Parabilis Medicines Inc. | $26.85 | -7.25% | $3.3B |
| SLS | SELLAS Life Sciences Group Inc. | $12.41 | +4.02% | $2.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier